Abstract:Oncology immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clinical responses. Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clinical trials. However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small molecules have far lagged behind. Small molecule immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access. Therefore, small molecule immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clinical response and drug resistance. Fortunately, remarkable progress has achieved recently in the pursuit of small molecule immunotherapy. This review intends to provide a timely highlight on those clinically investigated small molecules targeting PD-1/PD-L1, IDO1, and STING. The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clinical testings. Small molecule PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clinical outcomes. Since no small molecule immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small molecules with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.

Recent advances in small molecule based cancer immunotherapy

Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions.

Small-molecule agents for cancer immunotherapy

If small molecules immunotherapy comes, can the prime be far behind?

Small-molecule Modulators of Tumor Immune Microenvironment

Small-Molecule Targets in Immuno-Oncology

Small Molecule- and Peptide-Based Approaches

Small molecule innate immune modulators in cancer therapy

Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy.

Small Molecules As PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

From Monoclonal Antibodies to Small Molecules: the Development of Inhibitors Targeting the Pd-1/Pd-L1 Pathway

PD-1/PD-L1 Inhibitors for Immuno-oncology: from Antibodies to Small Molecules

Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status

The expanding role for small molecules in immuno-oncology

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Emerging immunological strategies: recent advances and future directions

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Recent Advances in Cancer Immunotherapy

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities